

TRANSFORMING DIABETIC RETINOPATHY CARE WITH ARTIFICIAL INTELLIGENCE

Abstract

Artificial intelligence (AI) has the potential to transform the care of diabetic retinopathy, a leading cause of vision loss in individuals with diabetes. The article highlights the transformative potential of AI in diabetic retinopathy diagnosis, risk stratification, treatment guidance, and prognosis. AI algorithms, including machine learning and deep learning models, have shown remarkable accuracy in diagnosing diabetic retinopathy and can aid in screening programs, optimizing efficiency and scalability. AI-based systems enable risk stratification, personalized treatment plans, and continuous monitoring of disease progression and treatment response, improving patient outcomes. However, ethical considerations, regulatory challenges, and the need for data standardization and algorithm interpretability must be addressed to ensure responsible implementation of AI. The integration of AI into diabetic retinopathy management holds promise for personalized medicine and reducing the burden of vision loss, but further research and collaboration are needed to overcome challenges and fully leverage AI's potential.

Keywords: Machine learning, Deep learning, Diagnostic imaging

Authors

Dr. Shashidhar K N

Professor and HOD
Department of Biochemistry
Sri Devaraj Urs Medical College
Tamaka, India
drshashikn1971@sduaher.ac.in

Dr. Harish R

Assistant Professor
Department of Biochemistry
Haveri Institute of Medical Sciences
Haveri, India
harishreddy1349@gmail.com

Dr. Prabhavathi K

Professor
Department of Biochemistry
Sri Devaraj Urs Medical College
Tamaka, India
prabhavathik@sduaher.ac.in

I. INTRODUCTION

Diabetic retinopathy (DR) is a leading cause of vision loss among individuals with diabetes. Regular eye screenings are crucial to detect and treat advanced stages of diabetic retinopathy, such as proliferative diabetic retinopathy and diabetic macular edema, before irreversible visual impairment occurs. Screening programs, implemented in various countries, have effectively reduced the risk of vision loss. However, the increasing number of diabetes patients burdens healthcare systems, emphasizing the need for automated solutions to improve screening efficiency and diagnostic accuracy [1].

Artificial intelligence (AI) is rapidly advancing and has the potential to revolutionize the diagnosis and management of diabetes, a global pandemic. Machine learning (ML) principles have been employed to develop algorithms that support predictive models for assessing the risk of developing diabetes and its associated complications. Digital therapeutics have emerged as effective interventions for lifestyle therapy in diabetes management. Empowering patients for self-management is on the rise, facilitated by clinical decision support systems that benefit both patients and healthcare professionals. AI enables continuous and remote monitoring of patient symptoms and biomarkers, eliminating the burden of frequent visits. Moreover, social media and online communities contribute to enhanced patient engagement in diabetes care. Technological advancements have optimized resource utilization in diabetes management. Collectively, these intelligent innovations have resulted in improved glycemic control, reducing fasting and postprandial glucose levels, glucose fluctuations, and glycosylated hemoglobin. AI is poised to bring a paradigm shift in diabetes care, shifting from conventional management approaches to targeted, data-driven precision care **Figure (1)** [2]. This chapter explores the transformative potential of AI in diabetic retinopathy care, highlighting its applications and key considerations.

II. DIAGNOSIS AND SCREENING OF DIABETIC RETINOPATHY

One area where AI is making significant strides is in healthcare, specifically in the prevention, diagnosis, and management of diseases. The field of ophthalmology is at the forefront of AI implementation in medicine due to its heavy reliance on imaging for disease diagnosis. Deep learning (DL)-based AI models have recently been applied to screen and predict the most prevalent causes of visual impairment and blindness, such as glaucoma, cataract, age-related macular degeneration (ARMD), and diabetic retinopathy (DR) [3]. AI algorithms, including machine learning and deep learning models, have shown remarkable accuracy in diagnosing diabetic retinopathy. By analyzing retinal images, AI systems can detect subtle signs of the disease, enabling early detection and intervention. AI also aids in screening programs by automating the analysis of large volumes of images, optimizing efficiency and scalability. The success of AI in medicine can largely be attributed to the development of deep learning algorithms, which are computational models consisting of multiple layers of simulated neurons. These algorithms have the ability to learn data representations at different levels of complexity. In the field of ophthalmology, the Inception-v3 algorithm and transfer learning concept have been employed to address DR [4]. The addition of deep learning (DL) features to the IDx-DR system resulted in improvements over the previous IDP system. The performance of the IDx-DR system was evaluated using the same publicly available dataset (Messidor-2) to assess the advantage provided by DL algorithms. While the sensitivity of the IDP system remained high at 96.8%, there was a significant enhancement in specificity with the IDx-DR system, achieving 87% specificity for

referable diabetic retinopathy (rDR). rDR included moderate diabetic retinopathy and vision threatening diabetic retinopathy. This improvement led to a substantial reduction in false-positive results [5]. Furthermore, the IDx-DR system underwent verification in a real-life scenario within a Dutch diabetic care system. Out of 1410 patients, 80.4% were deemed to have images of sufficient quality by three independent human graders, while the IDx-DR system accepted 66.3% of the images. However, concerns were raised regarding the use of the system's built-in re-imaging prompt [6].

These findings demonstrate that the incorporation of DL features in the IDx-DR system has yielded improved specificity in detecting rDR, reducing the number of false-positive exams. Additionally, real-life verification within a Dutch diabetic care system has provided insights into the system's performance, although challenges related to the use of the built-in re-imaging prompt have been highlighted. Current version of IDx-DR device, version 2.1 is able to differentiate between no DR and mild DR [5].

RetmarkerDR software, a Class IIa medical device with a CE mark, was developed in Portugal and has been utilized in diabetic retinopathy (DR) screening locally for several years. It was incorporated into an existing DR screening program conducted in central Portugal since 2011, where it plays a role in the initial sorting of images into "disease" or "no disease" categories. The software identifies cases that require further assessment by human graders within the "disease" subgroup. The study by Ribeiro et al. provides detailed protocols and additional information on the implementation of RetmarkerDR. The software utilizes feature-based machine learning algorithms to support its functionality [7].

EyeArt, developed by Eyenuk Inc. in Los Angeles, USA, is a Class IIa medical device categorized as such in the EU and is commercially available in Canada. However, its use in the US is currently limited to investigational purposes. Eyenuk Inc. also offers another product called Eyemark, which tracks the progression of diabetic retinopathy (DR) and provides measurements of microaneurysm (MA) turnover, similar to RetmarkerDR. EyeArt has the capability to capture a variable number of retinal images during a patient encounter. It automatically excludes images that are of insufficient quality or unrelated to the inner eye. Additionally, the system can analyze images from the patient's previous encounters to estimate MA turnover. EyeArt operates as a cloud-based system and provides an application programming interface (API) for seamless integration into existing imaging and telescreening software [8].

Retalyze is cloud-based software used for analyzing fundus images, providing automated screening for diabetic retinopathy (DR), age-related macular degeneration (AMD), and more recently, glaucoma. It is classified as a Class I medical device with a CE mark. The system allows image submission through a secure website-based platform with end-to-end encryption. The initial scientific reports on the efficacy of Retalyze date back to 2003, with studies conducted on cohorts of 137, 100, and 83 patients, respectively. These early reports utilized images captured on 35mm film and employed lesion-based detection methods. The studies reported sensitivities ranging from 71.4% to 93.1% and specificities ranging from 71.6% to 96.7% [9, 10, 11]. Following the publication of these early results, Retalyze underwent a period of commercial unavailability until its reintroduction in 2013 in its current web-based form, incorporating modern deep learning improvements. However, there is a lack of recent studies assessing its efficacy in this updated form. It is important to note that due to the absence of recent studies, the current effectiveness of Retalyze in its web-based version

remains unclear. Further research is warranted to evaluate its performance and validate its efficacy in the context of modern deep learning advancements.

AI plays a vital role in identifying patients at higher risk for disease progression and poor visual outcomes. By leveraging machine learning algorithms and patient data, AI models can predict disease trajectory and personalize treatment plans. These AI-driven risk stratification approaches enable targeted monitoring, intervention, and resource allocation for improved patient management.

III. TREATMENT AND MANAGEMENT

Most recently, the molecular classification of breast cancer is being Artificial intelligence (AI) can play a crucial role in optimizing the management of diabetic retinopathy, ensuring that the right patient receives the right treatment at the right time and place, leading to improved care and outcomes. Currently, the management of mild diabetic retinopathy focuses on preventive measures to slow its progression, including tight glucose control and addressing risk factors like elevated blood pressure.

For severe diabetic retinopathy, including diabetic macular edema (DME) and proliferative diabetic retinopathy, interventions such as laser photocoagulation and anti-VEGF injections are employed. However, treatment response to modalities like anti-VEGF therapy can vary among patients. Recent studies have demonstrated that deep learning algorithms can effectively predict DME patients who are more likely to respond to anti-VEGF treatment based on pre-treatment Optical Coherence Tomography (OCT) imaging scans [12]. This provides insights into phenotypic variations and highlights clinical factors that contribute to different treatment outcomes, facilitating the development of personalized management approaches. Moreover, AI has been successfully utilized to detect morphological changes in the retina associated with drug effects in diabetic retinopathy [13]. This helps draw clinicians' attention to human factors like compliance, which can explain variations in outcomes through objective markers. These AI applications in diabetic retinopathy management pave the way for personalized medicine enabled by AI systems, allowing for tailored approaches for patients with diabetic retinopathy.

Overall, the integration of AI into diabetic retinopathy management holds immense potential in optimizing treatment decisions, identifying treatment responders, and understanding the underlying factors contributing to variations in outcomes. It opens up new avenues for personalized medicine, enhancing the care and outcomes of patients with diabetic retinopathy. AI assists in treatment decision-making by providing recommendations for interventions such as laser therapy, intravitreal injections, and anti-VEGF therapy. By analyzing patient-specific data and treatment outcomes, AI models guide healthcare professionals in selecting the most effective and personalized treatment options. This improves treatment outcomes, reduces unnecessary interventions, and optimizes patient care.

IV. MONITORING DISEASE PROGRESSION AND TREATMENT RESPONSE

AI-based systems offer continuous monitoring of diabetic retinopathy progression and treatment response. By analyzing longitudinal data, including retinal images and clinical outcomes, AI models can detect subtle changes, predict disease worsening, and evaluate treatment effectiveness. This facilitates timely interventions and personalized care, improving

patient outcomes. Recently, deep learning algorithms have been proposed to predict diabetic retinopathy (DR) progression using color fundus photographs (CFPs) obtained from a single visit. These algorithms were designed to forecast future DR progression, specifically defined as a 2-step worsening on the Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale. The models were trained using DR severity scores assessed by well-trained human reading center graders at 6, 12, and 24 months from the baseline visit, with their assessments being masked. One of the models, focusing on prediction at the 12-month mark, achieved a performance indicated by an area under the curve (AUC) value of 0.79. Notably, these findings emphasize the significance of the predictive signals present in the peripheral retinal fields, which are not routinely collected during DR assessments, as well as the importance of microvascular abnormalities [14].

The feasibility of predicting future DR progression using CFPs from a single visit has been demonstrated. With further development on larger and more diverse datasets, such an algorithm could facilitate early diagnosis and prompt referral to a retina specialist for more frequent monitoring and potentially early intervention. Additionally, it has the potential to enhance patient recruitment for clinical trials targeting DR.

V. ETHICAL CONSIDERATIONS

The use of AI in diabetic retinopathy care raises ethical considerations, including patient privacy, data security, and patient autonomy. Protecting patient data, ensuring secure storage and transmission, and promoting transparency in AI algorithms are essential. Respecting patient autonomy by providing explanations and involving patients in treatment decisions are critical aspects of responsible AI deployment.

Implementing AI systems in clinical practice requires addressing regulatory challenges. Establishing guidelines and approval processes specific to AI algorithms and diabetic retinopathy are necessary. Validating AI models across diverse populations, standardizing datasets, and addressing algorithm interpretability and fairness are vital steps. Collaboration between regulators, healthcare professionals, researchers, and technology developers is the key to navigating these challenges.

Companies have a responsibility to ensure the proper and safe functioning of AI algorithms when used as intended, but they may not be held responsible for off-label uses. In terms of the legal considerations surrounding AI, for instance, the creators of the AI device must assume liability for any harm resulting from its diagnostic output when used correctly and in accordance with approved indications. When it comes to off-label use, the responsibility for ensuring appropriateness may appear to fall on the healthcare provider. However, the delicate nature of these AI models means that even strong associations between patient outcomes and off-label postmarket AI usage can be undermined if subtle changes in patient characteristics lead to flawed results from the algorithm. It is crucial to recognize the complexities and potential limitations associated with off-label use of AI algorithms. While companies are accountable for the performance of their algorithms within approved indications, the responsibility for assessing the appropriateness and accuracy of off-label usage may rest with healthcare providers, considering the potential risks and limitations associated with these applications [15].

It is true that AI systems, including machine learning and deep learning platforms, can potentially misdiagnose patients if they have been trained on incomplete or inadequate datasets. These systems require large amounts of historical data, such as fundus photography, to learn and identify specific features associated with particular conditions. However, when presented with a novel image that is atypical or falls outside its trained parameters, the AI model may provide false or nonsensical answers. One of the challenges with AI systems is the lack of transparency, making it difficult to explain why a specific failure occurred. Without transparency, it becomes challenging to pinpoint the exact reasons behind the AI model's incorrect response. In cases where the model encounters images or conditions not adequately represented in the training set, it may struggle to provide accurate results [16].

Furthermore, the issue of missing or necessary data becomes opaque when attempting to identify the cause of such failures. While a general explanation may be that the training set lacks diversity, the specific data that are missing or required for optimal performance may not be readily identifiable. Addressing these limitations and improving transparency in AI systems is an ongoing area of research. Efforts are being made to develop methods that enhance model interpretability and provide insights into the decision-making process of AI algorithms. Additionally, expanding and diversifying training datasets can help mitigate these challenges, enabling AI systems to better handle atypical cases and reduce the risk of false answers.

VI. CONCLUSION

The future of AI in diabetic retinopathy care is promising. Emerging technologies, such as augmented reality and virtual reality, hold potential for enhanced visualization and interpretation of retinal images. Integration of AI with other imaging modalities and genetic data may provide comprehensive insights for personalized medicine approaches. Ongoing research and interdisciplinary collaborations will continue to drive advancements and address challenges. Artificial intelligence has the transformative potential to revolutionize the care of diabetic retinopathy. By improving diagnosis accuracy, enabling personalized treatment decisions, and monitoring disease progression, AI enhances patient outcomes and reduces the burden of vision loss. Adhering to ethical considerations, addressing regulatory challenges, and fostering collaboration are crucial to ensure responsible and effective integration of AI in diabetic retinopathy care.




Figure 1: Role of Artificial Intelligence in Diabetic Retinopathy

REFERENCES

- [1] Grauslund J. Diabetic retinopathy screening in the emerging era of artificial intelligence. *Diabetologia*. 2022 Sep;65(9):1415-1423. doi: 10.1007/s00125-022-05727-0. Epub 2022 May 31. PMID: 35639120.
- [2] Ellahham S. Artificial Intelligence: The Future for Diabetes Care. *Am J Med*. 2020 Aug;133(8):895-900. doi: 10.1016/j.amjmed.2020.03.033. Epub 2020 Apr 20. PMID: 32325045.
- [3] Sheng B, Chen X, Li T, Ma T, Yang Y, Bi L, Zhang X. An overview of artificial intelligence in diabetic retinopathy and other ocular diseases. *Front Public Health*. 2022 Oct 28; 10:971943. doi: 10.3389/fpubh.2022.971943. PMID: 36388304; PMCID: PMC9650481.
- [4] Sahlsten J, Jaskari J, Kivinen J, Turunen L, Jaanio E, Hietala K, Kaski K. Deep Learning Fundus Image Analysis for Diabetic Retinopathy and Macular Edema Grading. *Sci Rep*. 2019 Jul 24; 9(1):10750. doi: 10.1038/s41598-019-47181-w. PMID: 31341220; PMCID: PMC6656880.
- [5] Abramoff MD, Lou Y, Erginay A, Clarida W, Amelon R, Folk JC, Niemeijer M. Improved Automated Detection of Diabetic Retinopathy on a Publicly Available Dataset Through Integration of Deep Learning. *Invest Ophthalmol Vis Sci*. 2016 Oct 1;57(13):5200-5206. doi: 10.1167/iovs.16-19964. PMID: 27701631.
- [6] van der Heijden AA, Abramoff MD, Verbraak F, van Hecke MV, Liem A, Nijpels G. Validation of automated screening for referable diabetic retinopathy with the IDx-DR device in the Hoorn Diabetes Care System. *Acta Ophthalmol*. 2018 Feb;96(1):63-68. doi: 10.1111/aos.13613. Epub 2017 Nov 27. PMID: 29178249; PMCID: PMC5814834.
- [7] Ribeiro L, Oliveira CM, Neves C, Ramos JD, Ferreira H, Cunha-Vaz J. Screening for Diabetic Retinopathy in the Central Region of Portugal. Added Value of Automated 'Disease/No Disease' Grading. *Ophthalmologica*. 2014 Nov 26. doi: 10.1159/000368426. Epub ahead of print. PMID: 25427567.
- [8] Solanki K, Ramachandra C, Bhat S, Bhaskaranand M, Nittala MG, Sadda SR. EyeArt: automated, high-throughput, image analysis for diabetic retinopathy screening. *Invest Ophthalmol Vis Sci*. 2015;56:1429-32.
- [9] Larsen N, Godt J, Grunkin M, Lund-Andersen H, Larsen M. Automated detection of diabetic retinopathy in a fundus photographic screening population. *Invest Ophthalmol Vis Sci*. 2003;44:767-71. doi: 10.1167/iovs.02-0417.
- [10] Hansen AB, Hartvig NV, Jensen MS, Borch-Johnsen K, Lund-Andersen H, Larsen M. Diabetic retinopathy screening using digital non-mydriatic fundus photography and automated image analysis. *Acta Ophthalmol Scand*. 2004;82:666-72. doi: 10.1111/j.1600-0420.2004.00350.x.
- [11] Larsen M, Godt J, Larsen N, Lund-Andersen H, Sjølie AK, Agardh E, et al. Automated detection of fundus photographic red lesions in diabetic retinopathy. *Invest Ophthalmol Vis Sci*. 2003;44:761-6. doi: 10.1167/iovs.02-0418.
- [12] Rasti R, Allingham MJ, Mettu PS, et al. Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema. *Biomed Opt Express* 2020; 11:1139-1152.
- [13] Xie Q, Liu Y, Huang H, et al. An innovative method for screening and evaluating the degree of diabetic retinopathy and drug treatment based on artificial intelligence algorithms. *Pharmacol Res* 2020; 159:104986.
- [14] Arcadu F, Benmansour F, Maunz A, Willis J, Haskova Z, Prunotto M. Deep learning algorithm predicts diabetic retinopathy progression in individual patients. *NPJ Digit Med*. 2019 Sep 20;2:92. doi: 10.1038/s41746-019-0172-3. Erratum in: *NPJ Digit Med*. 2020 Dec 8;3(1):160. PMID: 31552296; PMCID: PMC6754451.
- [15] Babic B, Gerke S, Evgeniou T, Cohen IG. Algorithms on regulatory lockdown in medicine. *Science*. 2019 Dec 6;366(6470):1202-1204. doi: 10.1126/science.aay9547. PMID: 31806804.
- [16] Evans NG, Wenner DM, Cohen IG, Purves D, Chiang MF, Ting DSW, Lee AY. Emerging Ethical Considerations for the Use of Artificial Intelligence in Ophthalmology. *Ophthalmol Sci*. 2022 Mar 7;2(2):100141. doi: 10.1016/j.xops.2022.100141. PMID: 36249707; PMCID: PMC9560632.